ADVFN ADVFN

Hot Features

Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
24.35
0.37
(1.54%)
終了 6月14日 5:00AM
24.10
-0.25
(-1.03%)
取引時間後: 8:59AM

Ultragenyx Pharmaceutical Inc (RARE) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

主要統計と詳細

通貨
24.10
( 0.50% )
買値
22.04
売値
25.87
出来高
1,846,764
24.005 日の範囲 24.81
18.00 52 週間の範囲 42.37
時価総額
前日終値
23.98
始値
24.10
最終取引時間
財務取引量
US$ 45,146,102
VWAP
24.4461
平均取引量 (3 か月)
US$ 1,847,736
発行済株式数
98,189,224
配当利回り
PER
-3.59
1 株当たり利益 (EPS)
-6.11
歳入
670M
純利益
-609M

Ultragenyx Pharmaceutical Inc について

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacif... Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company’s products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California. 詳細を表示

セクター
Healthcare
業界
Biotechnology & Life Sciences
ウェブサイト
本社
Novato, United States
設立
2026
Ultragenyx Pharmaceutical Inc is listed in the Healthcare sector of the ナスダック市場 with ticker RARE. The last closing price for Ultragenyx Pharmaceutical was US$23.98. Over the last year, Ultragenyx Pharmaceutical shares have traded in a share price range of US$ 18.00 to US$ 42.37.

Ultragenyx Pharmaceutical currently has 98,189,224 shares in issue. The market capitalisation of Ultragenyx Pharmaceutical is US$2.37 billion. Ultragenyx Pharmaceutical has a price to earnings ratio (PE ratio) of -3.59.

Ultragenyx Pharmaceutical (RARE) のオプションフロー概要

全体の流れ

ベアリッシュ

ネットプレミアム

-893k

Calls / Puts

33.33%

買い / 売り

300.00%

OTM / ITM

100.00%

Sweeps比率

0.00%

RARE 最新ニュース

期間 †前日比前日比 %始値高値安値平均出来高VWAP
10.793.389103389123.3124.3521.39142584022.65270182CS
4-1.61-6.2621548035825.7125.9521.33157046823.08698217CS
123.5817.446393762220.5227.4218.29174109623.21147518CS
26-12.29-33.773014564436.3936.811318223982723.33919203CS
52-13.27-35.509767192937.3742.3718198123026.82565052CS
156-27.69-53.465920061851.7960.3718119560434.00392526CS
260-79.75-76.7934520944103.85105.5061895266840.10747302CS

RARE - Frequently Asked Questions (FAQ)

What is the current Ultragenyx Pharmaceutical Inc share price?
The current share price of Ultragenyx Pharmaceutical Inc is US$ 24.10
How many Ultragenyx Pharmaceutical Inc shares are in issue?
Ultragenyx Pharmaceutical Inc has 98,189,224 shares in issue
What is the market cap of Ultragenyx Pharmaceutical Inc?
The market capitalisation of Ultragenyx Pharmaceutical Inc is USD 2.37B
What is the 1 year trading range for Ultragenyx Pharmaceutical Inc share price?
Ultragenyx Pharmaceutical Inc has traded in the range of US$ 18.00 to US$ 42.37 during the past year
What is the PE ratio of Ultragenyx Pharmaceutical Inc?
The price to earnings ratio of Ultragenyx Pharmaceutical Inc is -3.59
What is the cash to sales ratio of Ultragenyx Pharmaceutical Inc?
The cash to sales ratio of Ultragenyx Pharmaceutical Inc is 3.21
What is the registered address of Ultragenyx Pharmaceutical Inc?
The registered address for Ultragenyx Pharmaceutical Inc is 60 Leveroni Court, Novato, California, 94949
What is the Ultragenyx Pharmaceutical Inc website address?
The website address for Ultragenyx Pharmaceutical Inc is www.ultragenyx.com
Which industry sector does Ultragenyx Pharmaceutical Inc operate in?
Ultragenyx Pharmaceutical Inc operates in the Biotechnology & Life Sciences sector

RARE 取引

さらに

取引は遅延しています

リアルタイムの取引を取得するには、アカウントをアップグレードしてください

リアルタイムにアップグレード

RARE Discussion

投稿を表示